Limits...
A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases.

Zhang L, Chen L, Xie Q, Zhang Y, Cheng L, Li H, Wang J - BMC Med Imaging (2015)

Bottom Line: The sensitivity, specificity, and accuracy with respect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging methods.It was found that (99m)Tc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI, 45.4-55.1%) sensitivity, 50.0% (95% CI, 18.8-81.2%) specificity, and 50.2% (95% CI, 45.5-55.1%) accuracy. 18F-FDG PET/CT achieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP whole-body BS (p<0.001).F-FDG PET/CT has a higher diagnostic value than (99m)Tc-MDP whole-body BS in the detection of osteolytic bone metastases, especially in the vertebra.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China. linzhangswh@yahoo.com.

ABSTRACT

Background: The objective of this study was to evaluate the feasibility and diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and (99m)Tc-methylenediphosphonate (MDP) whole-body bone scanning (BS) for the detection of osteolytic bone metastases.

Methods: Thirty-four patients with pathologically confirmed malignancies and suspected osteolytic bone metastases underwent 18F-FDG PET/CT and (99m)Tc-MDP whole-body BS within 30 days. The sensitivity, specificity, and accuracy with respect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging methods.

Results: The sensitivity, specificity, and accuracy of 18F-FDG PET/CT for the diagnosis of osteolytic bone metastases were 94.3% (95% confidence interval [CI], 91.6-96.2%), 83.3% (95% CI, 43.6-96.9%), and 94.2% (95% CI, 91.5-96.1%), respectively. It was found that (99m)Tc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI, 45.4-55.1%) sensitivity, 50.0% (95% CI, 18.8-81.2%) specificity, and 50.2% (95% CI, 45.5-55.1%) accuracy. 18F-FDG PET/CT achieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP whole-body BS (p<0.001).

Conclusions: F-FDG PET/CT has a higher diagnostic value than (99m)Tc-MDP whole-body BS in the detection of osteolytic bone metastases, especially in the vertebra.

Show MeSH

Related in: MedlinePlus

A 54-year-old woman with left lung cancer. Bone scanning (BS) shows focally increased uptake in the left ninth, tenth, and twelfth posterior ribs, three to five lumbar vertebrae and nearby regions of the lesser trochanter of the right femur (A). PET-CT revealed increased 18FDG intake at the left tenth posterior rib, right ilium, and right femur; the maximum standardized uptake value was 12.6 (B and C). More metastatic lesions were detected using 99mTc-MDP BS than 18F-FDG PET-CT.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4358702&req=5

Fig3: A 54-year-old woman with left lung cancer. Bone scanning (BS) shows focally increased uptake in the left ninth, tenth, and twelfth posterior ribs, three to five lumbar vertebrae and nearby regions of the lesser trochanter of the right femur (A). PET-CT revealed increased 18FDG intake at the left tenth posterior rib, right ilium, and right femur; the maximum standardized uptake value was 12.6 (B and C). More metastatic lesions were detected using 99mTc-MDP BS than 18F-FDG PET-CT.

Mentions: The diagnoses made using 18F-FDG PET/CT and BS are described in Table 5. The number of positive and negative lesions identified using 18F-FDG PET/CT were 388 and 319, respectively; 99mTc-MDP BS images revealed 207 positive and 501 negative lesions. There was no significant difference in the diagnostic consistency of the two methods (p<0.001); their consistency was poor as shown in Figures 3 and 4.Table 5


A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases.

Zhang L, Chen L, Xie Q, Zhang Y, Cheng L, Li H, Wang J - BMC Med Imaging (2015)

A 54-year-old woman with left lung cancer. Bone scanning (BS) shows focally increased uptake in the left ninth, tenth, and twelfth posterior ribs, three to five lumbar vertebrae and nearby regions of the lesser trochanter of the right femur (A). PET-CT revealed increased 18FDG intake at the left tenth posterior rib, right ilium, and right femur; the maximum standardized uptake value was 12.6 (B and C). More metastatic lesions were detected using 99mTc-MDP BS than 18F-FDG PET-CT.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4358702&req=5

Fig3: A 54-year-old woman with left lung cancer. Bone scanning (BS) shows focally increased uptake in the left ninth, tenth, and twelfth posterior ribs, three to five lumbar vertebrae and nearby regions of the lesser trochanter of the right femur (A). PET-CT revealed increased 18FDG intake at the left tenth posterior rib, right ilium, and right femur; the maximum standardized uptake value was 12.6 (B and C). More metastatic lesions were detected using 99mTc-MDP BS than 18F-FDG PET-CT.
Mentions: The diagnoses made using 18F-FDG PET/CT and BS are described in Table 5. The number of positive and negative lesions identified using 18F-FDG PET/CT were 388 and 319, respectively; 99mTc-MDP BS images revealed 207 positive and 501 negative lesions. There was no significant difference in the diagnostic consistency of the two methods (p<0.001); their consistency was poor as shown in Figures 3 and 4.Table 5

Bottom Line: The sensitivity, specificity, and accuracy with respect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging methods.It was found that (99m)Tc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI, 45.4-55.1%) sensitivity, 50.0% (95% CI, 18.8-81.2%) specificity, and 50.2% (95% CI, 45.5-55.1%) accuracy. 18F-FDG PET/CT achieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP whole-body BS (p<0.001).F-FDG PET/CT has a higher diagnostic value than (99m)Tc-MDP whole-body BS in the detection of osteolytic bone metastases, especially in the vertebra.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China. linzhangswh@yahoo.com.

ABSTRACT

Background: The objective of this study was to evaluate the feasibility and diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and (99m)Tc-methylenediphosphonate (MDP) whole-body bone scanning (BS) for the detection of osteolytic bone metastases.

Methods: Thirty-four patients with pathologically confirmed malignancies and suspected osteolytic bone metastases underwent 18F-FDG PET/CT and (99m)Tc-MDP whole-body BS within 30 days. The sensitivity, specificity, and accuracy with respect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging methods.

Results: The sensitivity, specificity, and accuracy of 18F-FDG PET/CT for the diagnosis of osteolytic bone metastases were 94.3% (95% confidence interval [CI], 91.6-96.2%), 83.3% (95% CI, 43.6-96.9%), and 94.2% (95% CI, 91.5-96.1%), respectively. It was found that (99m)Tc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI, 45.4-55.1%) sensitivity, 50.0% (95% CI, 18.8-81.2%) specificity, and 50.2% (95% CI, 45.5-55.1%) accuracy. 18F-FDG PET/CT achieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP whole-body BS (p<0.001).

Conclusions: F-FDG PET/CT has a higher diagnostic value than (99m)Tc-MDP whole-body BS in the detection of osteolytic bone metastases, especially in the vertebra.

Show MeSH
Related in: MedlinePlus